Arenaviruses used in treatments of prostate cancer
AssigneeHookipa Biotech GmbH
InventorsIgor Matushansky, Andy Hwang, Kianoosh Katchar, Henning Lauterbach, Klaus Orlinger, Sarah Schmidt, Felix Stemeseder
Life of this patent
Estimating the term…
Loading patent…
AssigneeHookipa Biotech GmbH
InventorsIgor Matushansky, Andy Hwang, Kianoosh Katchar, Henning Lauterbach, Klaus Orlinger, Sarah Schmidt, Felix Stemeseder
Estimating the term…
The present application relates to arenaviruses expressing prostate cancer-related antigens. In particular, described herein is a modified arenavirus particle which is engineered to carry a heterologous open reading frame (ORF) encoding a prostate cancer-related antigen or an antigenic fragment thereof, wherein the prostate cancer-related antigen is selected from the group consisting of: prostatic acid phosphatase (PAP), prostate specific antigen (PSA), and prostate-specific membrane antigen (PSMA). Also described herein are arenavius genome segments or S segments encoding the prostate cancer-related antigen or an antigenic fragment thereof, cDNA, DNA expression vector, a pharmaceutical composition comprising such an arenavirus particle, methods of generating such an arenavirus particle and treating prostate cancer using such an arenavirus particle, and a kit for such usage.
An arenavirus S segment, wherein the arenavirus S segment is engineered to carry an open reading frame (ORF) encoding a prostate cancer-related antigen or an antigenic fragment thereof, wherein the prostate cancer-related antigen is selected from the group consisting of:
A tri-segmented arenavirus particle comprising one arenavirus L segment and two arenavirus S segments, wherein a first arenavirus S segment is engineered to carry a heterologous ORF consisting of SEQ ID NO:
A tri-segmented arenavirus particle comprising one arenavirus L segment and two arenavirus S segments, wherein a first arenavirus S segment is engineered to carry a heterologous ORF consisting of SEQ ID NO:
A tri-segmented arenavirus particle comprising one arenavirus L segment and two arenavirus S segments, wherein a first arenavirus S segment is engineered to carry a heterologous ORF consisting of SEQ ID NO:
A tri-segmented arenavirus particle comprising two S segments, wherein one of the two S segments comprises SEQ ID NO. 10, and the other one of the two S segments comprises SEQ ID NO. 11.
A tri-segmented arenavirus particle comprising two S segments, wherein one of the two S segments comprises SEQ ID NO. 12, and the other one of the two S segments comprises SEQ ID NO. 13.
A tri-segmented arenavirus particle comprising two S segments, wherein one of the two S segments comprises SEQ ID NO. 14, and the other one of the two S segments comprises SEQ ID NO. 15.
A tri-segmented arenavirus particle comprising two S segments, wherein one of the two S segments comprises SEQ ID NO. 16, and the other one of the two S segments comprises SEQ ID NO. 17.
Dependencies are inferred from the claim text.